Messenger RNA specialist Moderna’s R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Messenger RNA specialist Moderna’s R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.